Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
US11499154B2 · kind B2 · utility
0Cited by
2References
14Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Apr 10, 2018 |
| Grant date | Nov 15, 2022 |
| Priority date | — |
| Expiry date | Sep 14, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y306/05005
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns the use of antisense oligonucleotides (AON) capable of inhibiting expression of dynamin 2, advantageously human dynamin 2, for use in the treatment of Charcot-Marie-Tooth disease (CMT) and centronuclear myopathies (CNM).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.